Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Stocks · News reference
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First Anniversary
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
8-K filing — Royalty Pharma plc (RPRX)
Filed: 2026-08-05 AccNo: 0001802768-26-000014 Size: 480 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
8-K filing — Theravance Biopharma, Inc. (TBPH)
Filed: 2026-08-25 AccNo: 0001104659-26-100860 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from